METHODS FOR TREATING PATIENTS HAVING CFH MUTATIONS WITH RECOMBINANT CFH PROTEINS
The present disclosure provides methods for treating, preventing, or inhibiting diseases in patients having one or more mutations in complement factor H (CFH), complement component 3 (C3), and complement factor B (CFB). Also provided are combination therapies comprising a CFH protein and a VEGF antagonist for treating neovascularization-associated ocular diseases..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Europäisches Patentamt - (2023) vom: 22. Nov. Zur Gesamtaufnahme - year:2023 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
MCLAUGHLIN JAMES [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2023-11-22, Last update posted on www.tib.eu: 2023-12-05, Last updated: 2023-12-08 |
|---|
| Patentnummer: |
EP4048318 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA014700417 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA014700417 | ||
| 003 | DE-627 | ||
| 005 | 20231208120741.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230215s2023 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA014700417 | ||
| 035 | |a (EPA)EP4048318 | ||
| 035 | |a (EPA)75620320 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a MCLAUGHLIN JAMES |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a METHODS FOR TREATING PATIENTS HAVING CFH MUTATIONS WITH RECOMBINANT CFH PROTEINS |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2023-11-22, Last update posted on www.tib.eu: 2023-12-05, Last updated: 2023-12-08 | ||
| 520 | |a The present disclosure provides methods for treating, preventing, or inhibiting diseases in patients having one or more mutations in complement factor H (CFH), complement component 3 (C3), and complement factor B (CFB). Also provided are combination therapies comprising a CFH protein and a VEGF antagonist for treating neovascularization-associated ocular diseases. | ||
| 650 | 4 | |a bio | |
| 650 | 4 | |a tec | |
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a G01N: Investigating or analysing materials by determining their chemical or physical properties (measuring or testing processes other than immunoassay, involving enzymes or microorganisms c12m, c12q) | |
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a C07K: Peptides (peptides containing β-lactam rings c07d;cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, c07d;ergot alkaloids of the cyclic peptide type c07d0519020000; single cell proteins, enzymes c12n;genetic engineering processes for obtaining peptides c12n0015000000) | |
| 650 | 4 | |a che | |
| 650 | 4 | |a C12Q: Measuring or testing processes involving enzymes, nucleic acids or microorganisms (immunoassay g01n0033530000); compositions or test papers therefor; processes of preparing such compositions; condition-responsive control in microbiological or enzymological processes | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a HUANG LISA |4 aut | |
| 700 | 0 | |a LAUDER SCOTT |4 aut | |
| 700 | 0 | |a KATTI SURESH |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2023) vom: 22. Nov. |
| 773 | 1 | 8 | |g year:2023 |g day:22 |g month:11 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/75620320/publication/EP4048318A1?q=EP4048318 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 936 | u | w | |j 2023 |b 22 |c 11 |
| 951 | |a AR | ||
| 952 | |j 2023 |b 22 |c 11 | ||